Ligand of Numb Protein X 4 (LNX4) is a nuanced component within the ubiquitin-proteasome system, serving as an E3 ubiquitin ligase that plays a pivotal role in the post-translational modification landscape, specifically in the ubiquitination and subsequent degradation of target proteins. This function is critical in regulating numerous cellular processes, including signal transduction, cell cycle progression, and neural development. By dictating the stability and localization of various proteins, LNX4 directly influences cellular dynamics and homeostasis. Its involvement in neural progenitor cell maintenance and neurogenesis underscores the protein's significance in developmental processes. The ubiquitination mediated by LNX4 is a finely tuned mechanism that ensures cellular adaptability and response to developmental cues, thereby maintaining the balance between stem cell renewal and differentiation necessary for proper neural development.
The inhibition of LNX4's ubiquitin ligase activity can result from multiple mechanisms, including the disruption of its interaction with E2 conjugating enzymes, hindrance of substrate recognition, or alterations in its structural integrity that impede its catalytic function. Such inhibition can have profound effects on cellular signaling pathways, particularly those involved in neurogenesis, by preventing the ubiquitination and degradation of LNX4 substrates, leading to their accumulation and potential dysregulation of signaling pathways. The specificity and regulation of LNX4 activity are further modulated by post-translational modifications, such as phosphorylation, which may alter its interaction with substrates or regulatory proteins. Additionally, competitive binding by pseudo substrates or negative regulators could sequester LNX4 away from its intended targets, effectively inhibiting its activity. Understanding the molecular mechanisms underlying the inhibition of LNX4 is crucial for deciphering its role in cellular processes and the potential consequences of its dysregulation. This knowledge could elucidate the pathways through which LNX4 influences neural development and the maintenance of cellular homeostasis, providing insights into the complex regulatory networks that dictate cell fate decisions and tissue integrity.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR (Epidermal Growth Factor Receptor) inhibitor, it blocks the tyrosine kinase activity of EGFR, hindering cell growth and division, mainly in certain cancers. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Targets the BCR-ABL tyrosine kinase, disrupting signaling pathways in chronic myeloid leukemia and gastrointestinal stromal tumors (GISTs). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including RAF, VEGFR, and PDGFR, affecting angiogenesis and cell proliferation, used in advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
An EGFR tyrosine kinase inhibitor, it disrupts EGFR signaling pathways, primarily used in non-small cell lung cancer | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets BCR-ABL, Src family kinases, and others, some forms of acute lymphoblastic leukemia. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Inhibits multiple receptor tyrosine kinases, including VEGFR and PDGFR, blocking angiogenesis and tumor growth, utilized in renal cell carcinoma and GISTs. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
A dual EGFR/HER2 inhibitor, it hinders the phosphorylation of EGFR and HER2 receptors, used in HER2-positive breast cancer. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Targets mTOR (mammalian target of rapamycin), inhibiting cell proliferation and angiogenesis, employed in advanced renal cell carcinoma and some cancers. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Specifically inhibits Bruton's tyrosine kinase (BTK), disrupting B-cell signaling, vital in B-cell malignancies like chronic lymphocytic leukemia (CLL). | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
A third-generation EGFR inhibitor, it targets T790M-mutant EGFR in non-small cell lung cancer, overcoming resistance to earlier EGFR inhibitors. | ||||||